Login to Your Account

Denosumab Phase III Cancer Trial Bodes Well for Amgen

By Trista Morriso

Thursday, July 9, 2009
Amgen Inc.'s denosumab - already under FDA review for bone loss - generated better-than-expected data in its first Phase III oncology trial, boosting confidence in ongoing studies and enhancing the drug's potential to offset Amgen's flagging core franchises. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription